Dr. Chavdarian brings over 30 years of novel product development and regulatory experience to the role
NEW DELHI, India, Nov. 13, 2017 (GLOBE NEWSWIRE) -- Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases affected by antibiotic-resistance, today announces that Charles G. Chavdarian, Ph.D., has been appointed senior vice president of product development and regulatory CMC (chemistry, manufacturing and controls), bringing more than 30 years of pharmaceutical R&D, commercial, and regulatory affairs experience to the Company. Dr. Chavdarian will lead product development strategies and oversee the regulatory process related to CMC of Vyome’s investigational products, including VB 1953, which is currently being evaluated in clinical safety & efficacy studies for the treatment of moderate to severe acne.
“Charles possesses a wealth of knowledge and experience in product development through all stages, as well as a strong understanding of regulatory affairs related to CMC,” said Venkateswarlu Nelabhotla (N. Venkat), co-founder and chief executive officer of Vyome. “He will be a valuable addition to our team as we further develop our dermatology pipeline.”
Prior to joining Vyome, Dr. Chavdarian served as the executive director of analytical sciences & regulatory CMC at Dow Pharmaceutical Sciences. Inc. Dr. Chavdarian also held management positions at Syntex Corp., Penederm Inc., ALZA Corp., Cellegy Pharmaceuticals and InSite Vision. He oversaw product development for novel prescription & OTC products in dermatology across various stages of development leading up to commercialization.
“I’m excited to join Vyome and lead the product and CMC development of VB 1953, which possesses the characteristics to be a potential best-in-class drug for the treatment of moderate to severe acne,” said Dr. Chavdarian. “I am also drawn to Vyome’s research pipeline and its proprietary Dual Action Rational Therapeutics (DART) platform, which has great potential to develop therapeutic options for patients facing skin diseases caused by opportunistic skin pathogens. I look forward to working with the team to further develop these therapeutics.”
Dr. Chavdarian received his bachelor of science in chemistry from the University of Michigan, Ann Arbor, and his doctorate in organic chemistry from the University of California, Berkeley. He then served a postdoctoral appointment in pharmaceutical chemistry at the University of California, San Francisco Medical Center. Dr. Chavdarian is the author of more than 35 technical publications and patents.
About Vyome Biosciences
Vyome Biosciences is an innovation-driven, clinical stage biopharmaceutical company, which has novel platform technologies and a deep pipeline of novel drugs for antibiotic resistant acne and other opportunistic pathogens. The company’s lead drug candidate, VB 1953, is a topical treatment product candidate for moderate to severe acne. VB 1953 has completed clinical Phase 1 & Proof of Concept efficacy studies and Vyome is currently initiating a Phase 2B study. Vyome has a deep pipeline of preclinical new chemical entities, which are unique in their ability to overcome the development of resistance and are based on its patented Dual Action Rational Therapeutics (DARTs) technology. Vyome has developed clinically proven antifungal products based on the innovative and patented technology platform Molecular Replacement Therapeutics (MRT™). Vyome has assembled a world-class team of scientific and business development experts from India and the United States who have a track record of conducting scientific research, developing breakthrough products and building sustainable businesses. More information is available at http://www.vyome.in and @VyomeBio.
Media contact:
Josephine Belluardo, Ph.D.
LifeSci Public Relations
(646) 751-4361
jo@lifescipublicrelations.com